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Chloroquine-resistant Plasmodium falciparum has 
now been reported from an increasing number of 
countries in western Africa. Recently, 2 reports 
suggested the probable emergence of chloroquine 
resistance in vivo in the Senegambian region (MENON 
et al., 1987; HELLGREN et al . ,  1987). In Senegal, 3 
isolates were found resistant in vitro in 1984/1985 
(BRANDICOURT et al . ,  1986; DRUILHE et al . ,  1986); 
however, since nearly 500 isolates studied during the 
period 1985-1988 were fully sensitive in vitro (com- 
bined unpublished data from: Brandicourt; Diouf; 
Diallo; Le Bras) and no resistant case observed in 
vivo,  Senegal was generally considered to be free from 
chloroquine resistance. 
We report here 3 cases of chloroquine resistance 
observed in October and November 1988 during a 
study conducted in Pikine, a suburb of Dakar in 
Senegal, were most children and adults are non- 
munune. 
The World Health Organization (WHO) 14-d 
extended test was successfully completed in 37 
patients aged 1-55 years with acute P .  fakiparum 
malaria. 34 (92% ) of the infections cleared after 
treatment (25 mg/kg over 3 d, tablets of Nivaquine9 
Specia) and did not recur during follow-up. 3 (8% ) of 
the infections were chloroquine-resistant (Table). 
Patient C.S. became apyretic and asymptomatic on 
day 1. Illness recurred on day 12. In vitro sensitivity 
was investigated by two methods: the standard WHO 
microtest and the 3-hypoxanthine semi-microtest. 
Table. Results of the 14-day test on 3 patients 
O 
3 
4 
5 
6 
7 
14 
Parasitaemia and temperature' 
C.S. B.D. W.T. 
(8 years) (3 Years) (11 years) 
22000 38'4 
6400 37'1 
880 36'7 
20 36'3 
o 37"4 
O 37"6 
O 37"6 
O 37"6 
1200 39"l 
48000 39"6 
160000 362 
3200 37"6 
68000 36*7 
1200 36"7 
24000 36"9 
1600 37"7 
3000 36"7 
56002 39"5' 
40000 38"6 
55000 379 
13000 36"7 
1400 36"6 
160 36"5 
240 36'6 
720 36"8 
2100 36"9 
11500 373  
'Parasrtaexnia per pl; axillary (W.T. and C.S.) or rectal temper 
'Day 12 values. 
(B.D.), "C. ORSTOM Fonds Documenire  
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Both tests indicated resistance, as schizonts matured 
in the presence of 6.4 pol/litre of chloroquine (32 
pmol per well, WHO microtest kits) and the 50% 
inhibitory concentration (IC50) was 400 nmolllitre 
(semi-microtest). Whole blood chloroquine (Cq) and 
monodesethylchloroquine (CqMI) concentrations on 
day 2 were 744 and 281 nmolllitre respectively 
(determined by high performance liquid chromo- 
tography): 
Patient B.D. became apyretic on day 1 but 
headaches were reported until day 3. Illness recurred 
on day 11. As can be seen in the Table, parasitaemia 
fluctuated markedly during follow-up, suggesting 
resistance at the RI11 level. Whole blood Cq and 
CqMl on day 2 were 966 and 140 nmoYlitre respec- 
tively. Sensitivity in vitro was not studied. 
Patient W.T. became apyretic on day 2 and 
asymptomatic (headache and weakness) on day 3. 
When the second treatment was given on day 20, 
parasite density was 29 OOO/fl and the temperature 
was 37.1"C. Careful examination and questioning 
failed to reveal any recurrence of fever or other 
symptoms. Tests in vitro indicated resistance: schi- 
zonts matured in the presence of 6.4 polllitre Cq 
(WHO microtest, day O and day 20 isolates); the ICso 
was 380 nmoYlitre (semi-microtest, day 20 isolate). 
Whole blood Cq and CqMl on day 2 were 1755 and 
545 nmoYlitre respectively (this patient had received 
20 mglkg by mistake on day 1). 
Ten years after the first report in Kenya (FOGH et 
al . ,  1979), this study demonstrates that chloroquine 
resistance in vivo has now reached the most westerly 
part of Africa. Furthermore, a high level of resistance 
was observed in 2 of the 3 first Senegalese cases, both 
of which were children who had never left the region 
of Dakar. Intensive surveys were carried out in 
Senegal during the period 1984-1988, and non- 
immune visitors to this country are numerous: it is 
interesting to note that 4 years separate the identifica- 
tion of a chloroquine-resistant strain from the emerg- 
ence of resistance in uivo. 
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